Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Mario Masellis

Showing results (321-330 of 338) with videos related to

Pageof 34
Sort By:
The Lancet. Neurology|February 10, 2015
Presymptomatic cognitive and neuroanatomical changes in genetic frontotemporal dementia in the Genetic Frontotemporal dementia Initiative (GENFI) study: a cross-sectional analysisJonathan D Rohrer, Jennifer M Nicholas, David M Cash, et al.
Annals of Neurology|September 24, 2022
Amyloid-Related Imaging Abnormalities in the DIAN-TU-001 Trial of Gantenerumab and Solanezumab: Lessons from a Trial in Dominantly Inherited Alzheimer DiseaseNelly Joseph-Mathurin, Jorge J Llibre-Guerra, Yan Li, et al.
Neurology|June 9, 2017
Diagnosis and management of dementia with Lewy bodies: Fourth consensus report of the DLB ConsortiumIan G McKeith, Bradley F Boeve, Dennis W Dickson, et al.
Alzheimer'S & Dementia : the Journal of the Alzheimer'S Association|November 1, 2022
Characteristics of the Ontario Neurodegenerative Disease Research Initiative cohortKelly M Sunderland, Derek Beaton, Stephen R Arnott, et al.
The Lancet. Neurology|March 22, 2025
Safety and efficacy of long-term gantenerumab treatment in dominantly inherited Alzheimer's disease: an open-label extension of the phase 2/3 multicentre, randomised, double-blind, placebo-controlled platform DIAN-TU trialRandall J Bateman, Yan Li, Eric M McDade, et al.
Journal of Alzheimer'S Disease : JAD|December 5, 2024
Impact of a national dementia research consortium: The Canadian Consortium on Neurodegeneration in Aging (CCNA)Howard Chertkow, Natalie Phillips, Kenneth Rockwood, et al.
Nature Medicine|June 22, 2021
A trial of gantenerumab or solanezumab in dominantly inherited Alzheimer's diseaseStephen Salloway, Martin Farlow, Eric McDade, et al.
Medrxiv : the Preprint Server for Health Sciences|February 20, 2025
Safety and efficacy of long-term gantenerumab treatment in dominantly inherited Alzheimer's disease: an open label extension of the phase 2/3 multicentre, randomised, double-blind, placebo-controlled platform DIAN-TU TrialRandall J Bateman, Yan Li, Eric M McDade, et al.
Medrxiv : the Preprint Server for Health Sciences|June 22, 2026
Trajectories of brain structure and function in young adult carriers of genetic frontotemporal dementia variantsIsis So, Jolina Lombardi, Adam M Staffaroni, et al.
Alzheimer'S & Dementia : the Journal of the Alzheimer'S Association|April 25, 2025
Sex differences in clinical phenotypes of behavioral variant frontotemporal dementiaXulin Liu, Sterre C M de Boer, Kasey Cortez, et al.
Pageof 34

Showing results (321-330 of 338) with videos related to

Sort By:
Pageof 34
The Lancet. Neurology|February 10, 2015
Presymptomatic cognitive and neuroanatomical changes in genetic frontotemporal dementia in the Genetic Frontotemporal dementia Initiative (GENFI) study: a cross-sectional analysisJonathan D Rohrer, Jennifer M Nicholas, David M Cash, et al.
Annals of Neurology|September 24, 2022
Amyloid-Related Imaging Abnormalities in the DIAN-TU-001 Trial of Gantenerumab and Solanezumab: Lessons from a Trial in Dominantly Inherited Alzheimer DiseaseNelly Joseph-Mathurin, Jorge J Llibre-Guerra, Yan Li, et al.
Neurology|June 9, 2017
Diagnosis and management of dementia with Lewy bodies: Fourth consensus report of the DLB ConsortiumIan G McKeith, Bradley F Boeve, Dennis W Dickson, et al.
Alzheimer'S & Dementia : the Journal of the Alzheimer'S Association|November 1, 2022
Characteristics of the Ontario Neurodegenerative Disease Research Initiative cohortKelly M Sunderland, Derek Beaton, Stephen R Arnott, et al.
The Lancet. Neurology|March 22, 2025
Safety and efficacy of long-term gantenerumab treatment in dominantly inherited Alzheimer's disease: an open-label extension of the phase 2/3 multicentre, randomised, double-blind, placebo-controlled platform DIAN-TU trialRandall J Bateman, Yan Li, Eric M McDade, et al.
Journal of Alzheimer'S Disease : JAD|December 5, 2024
Impact of a national dementia research consortium: The Canadian Consortium on Neurodegeneration in Aging (CCNA)Howard Chertkow, Natalie Phillips, Kenneth Rockwood, et al.
Nature Medicine|June 22, 2021
A trial of gantenerumab or solanezumab in dominantly inherited Alzheimer's diseaseStephen Salloway, Martin Farlow, Eric McDade, et al.
Medrxiv : the Preprint Server for Health Sciences|February 20, 2025
Safety and efficacy of long-term gantenerumab treatment in dominantly inherited Alzheimer's disease: an open label extension of the phase 2/3 multicentre, randomised, double-blind, placebo-controlled platform DIAN-TU TrialRandall J Bateman, Yan Li, Eric M McDade, et al.
Medrxiv : the Preprint Server for Health Sciences|June 22, 2026
Trajectories of brain structure and function in young adult carriers of genetic frontotemporal dementia variantsIsis So, Jolina Lombardi, Adam M Staffaroni, et al.
Alzheimer'S & Dementia : the Journal of the Alzheimer'S Association|April 25, 2025
Sex differences in clinical phenotypes of behavioral variant frontotemporal dementiaXulin Liu, Sterre C M de Boer, Kasey Cortez, et al.
Pageof 34